

WORLD HEALTH ORGANIZATION GLOBAL STRATEGY FOR THE  
SURVEILLANCE AND MONITORING OF HIV DRUG RESISTANCE

2012



World Health  
Organization



**WORLD HEALTH ORGANIZATION GLOBAL STRATEGY FOR THE  
SURVEILLANCE AND MONITORING OF HIV DRUG RESISTANCE**

2012

WHO Library Cataloguing-in-Publication Data

World Health Organization global strategy for the surveillance and monitoring of HIV drug resistance: an update.

1.Anti-HIV agents – therapeutic use. 2.Drug resistance, Viral – drug effects. 3.HIV infections – epidemiology. 4.HIV infections – drug therapy 5.Population surveillance. 6.Sentinel surveillance. 7.Developing countries. I.World Health Organization.

ISBN 978 92 4 150476 8

(NLM classification: QV 268.5)

© **World Health Organization 2012**

All rights reserved. Publications of the World Health Organization are available on the WHO web site ([www.who.int](http://www.who.int)) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland, (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [bookorders@who.int](mailto:bookorders@who.int)).

Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press through the WHO web site ([http://www.who.int/about/licensing/copyright\\_form/en/index.html](http://www.who.int/about/licensing/copyright_form/en/index.html)).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Layout by L'IV Com Sàrl, Villars-sous-Yens, Switzerland.

Printed by the WHO Document Production Services, Geneva, Switzerland.

# CONTENTS

Acronyms and abbreviations. . . . . 2

Introduction . . . . . 3

Monitoring HIV drug resistance early warning indicators (EWI). . . . . 5

Surveillance of HIV drug resistance in populations prior to treatment initiation and among those receiving ART . . . . . 7

Cross-sectional surveys of HIV drug resistance in adults prior to ART initiation at representative ART clinics. . . . . 8

Cross-sectional surveys of acquired HIV drug resistance in adults and children on ART for more than 12 months at nationally representative ART clinics . . . . . 10

Surveys of HIV drug resistance in children less than 18 months of age . . . . . 12

Surveys of transmitted drug resistance (TDR) in recently infected populations. . . . . 14

Implementation and funding HIV drug resistance surveillance activities within national ART programmes . . . . . 16

References . . . . . 17

# ACRONYMS AND ABBREVIATIONS

<b>ANC</b>	Antenatal clinic
<b>ART</b>	Antiretroviral therapy
<b>ARV</b>	Antiretroviral
<b>CDC</b>	Centers for Disease Control and Prevention
<b>DBS</b>	Dried blood spots
<b>DRM</b>	Drug resistant mutation
<b>EID</b>	Early infant diagnosis
<b>EWI</b>	Early warning indicator
<b>HIVDR</b>	HIV drug resistance
<b>LMIC</b>	Low and middle income countries
<b>LPV/r</b>	Lopinavir/ritonavir
<b>NNRTI</b>	Non-nucleoside reverse transcriptase inhibitor
<b>NRTI</b>	Nucleoside/nucleotide reverse transcriptase inhibitor
<b>NVP</b>	Nevirapine
<b>PEPFAR</b>	President's Emergency Plan for AIDS Relief
<b>PI</b>	Protease inhibitor
<b>PMTCT</b>	Prevention of mother to child transmission
<b>TDR</b>	Transmitted drug resistance
<b>UNGASS</b>	United Nations General Assembly Special Session on HIV/AIDS
<b>VCT</b>	Voluntary counseling and testing

## INTRODUCTION

As of the end of 2011, more than 8 million people in low- and middle-income countries (LMIC) were receiving antiretroviral therapy (ART), up from 6.6 million in 2010 – representing an increase of about 20% (1). This figure reflects a remarkable scale-up in the provision of ART from 400,000 people receiving it in 2003 at the launch of the “3 by 5” initiative. This dramatic increase has been attributed to multiple factors, including the use of standardized and simplified regimens and guidelines for initiation and monitoring of ART. Low- and middle-income countries have benefited from international donors such as the President’s Emergency Plan for AIDS Relief (PEPFAR) and the Global Fund to Fight AIDS, TB, and Malaria. Recipient countries have committed to the expansion and strengthening of their health systems to provide universal access to ART.

Despite the obvious benefits that rapid scale-up has had on AIDS-related morbidity and mortality, the potential for widespread emergence and transmission of HIV drug resistance (HIVDR) to antiretrovirals (ARVs) has been a major ongoing concern of public health experts. In 2004, in response to this concern, the World Health Organization (WHO) created HIVResNet, a global network of over 50 institutions, laboratories, clinicians, epidemiologists, and other HIVDR experts to support development and implementation of a of global drug resistance surveillance strategy (2).

In 2004, WHO and the United States Centers for Disease Control and Prevention (CDC), in collaboration with HIVResNet, developed a global strategy for the assessment and prevention of HIVDR. Components of the strategy included: 1) Formation of national HIVDR working groups in countries scaling-up ART, 2) Monitoring the quality of care in ART programmes using “Early Warning Indicators” of HIVDR (EWI), 3) Surveillance of acquired HIVDR at sentinel ART clinics, 4) Surveillance of transmitted drug resistant HIV in recently infected populations, 5) Designation, by national HIVDR working groups, of one or more HIVDR testing (genotyping) laboratories for HIVDR surveillance, and 6) Formation and maintenance of a national HIVDR database. Additionally the strategy included the development of a network of HIVDR genotyping laboratories that support public health surveillance.


As seen in the recently released WHO Global Report on HIV Drug Resistance (3) (July 2012) and in a recently published supplement in *Clinical Infectious Disease* (4) (May 2012), surveys using WHO surveillance methods have yielded valuable information about transmitted and acquired HIVDR in the setting of the rapid scale-up of ART. However, lessons learned from implementation of the WHO strategy and the realities of ongoing expansion of ART programmes suggested that parts of the strategy require updating. Therefore, WHO in consultation with HIVResNet updated its guidance on monitoring the quality of care in ART programmes related to HIVDR prevention using EWIs. Updates to guidance on surveillance of acquired HIVDR and surveillance of transmitted drug resistant HIV in recently infected populations were initiated. Additionally, new guidance on surveillance of HIVDR in children

less than 18 months of age and surveillance of HIVDR in populations initiating ART has been developed.

This document provides an overview of the different strategy elements, so as to inform its implementation in resource-limited settings. The guidance on the development and ongoing activity of national HIVDR working groups and the designation of WHO-recommended genotyping laboratories for drug resistance testing, as described previously remains unchanged (5).

The updated 2012 global HIVDR surveillance and monitoring strategy (Figure 1) presented in this document summarizes a comprehensive package of HIVDR surveys that should be implemented in all countries scaling-up and maintaining populations on ART.

**Figure 1.** WHO 2012 HIV drug resistance surveillance and monitoring strategy



预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_28325](https://www.yunbaogao.cn/report/index/report?reportId=5_28325)

